Pathogen Inactivated Platelets use in Pediatric Patients: The International Experience (PIPPP Study)

The use of pathogen inactivated (PI) blood products is slowly increasing throughout the world. The promise of PI is immense, to decrease the rate of pathogen transmission through the blood supply. The uptake of the technology has been slower in the USA compared to the EU countries, many of which have broadly implemented PI platelet transfusions throughout their catchment area. Further, as the USA and other parts of the world are contemplating bringing in PI products, questions arise about the use and safety of these treated blood products in pediatric and neonatal patients.

Completed

151

CTS

Delaney